1. Scrip
  2. >>Leadership

Biogen Lures Viehbacher Back From Venture Capital As CEO

 
• By Jessica Merrill

Christopher Viehbacher, former Sanofi CEO and current managing partner at Gurnet Capital, will be charged with returning Biogen to growth with a second big Alzheimer’s launch looming.

Biogen building
Biogen appointed a new CEO • Source: Shutterstock

Biogen, Inc.'s next CEO will be former Sanofi CEO turned venture capitalist Christopher Viehbacher, who will step into a challenging role leading Biogen through an uncertain growth period and executing on a complicated Alzheimer's commercial strategy. The company announced on 10 November that Viehbacher will succeed Michel Vounatsos as president and CEO effective on 14 November.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.